194039-07-1

Upstream product

• 617-04-9 (2R,3S,4S,5S,6S)-2-(hydroxymethyl)-6-methoxytetrahydro-2H-pyran-3,4,5-triol 
• 3150-15-0 methyl 2,3-anhydro-4,6-O-benzilidene-α-D-mannopyranoside 
• 97-30-3 methyl-alpha-D-glucopyranoside 
• 3162-96-7 4,6-O-benzylidene-1-O-methyl-α-D-glucopyranoside 
• 74410-51-8 methyl 4,6-O-benzylidene-3-O-benzyl-α-D-altropyranoside 

Downstream Products

• 203925-45-5 1-[(2R,4aR,6R,7R,8R,8aR)-8-Benzyloxy-7-(tert-butyl-dimethyl-silanyloxy)-2-(4-methoxy-phenyl)-hexahydro-pyrano[3,2-d][1,3]dioxin-6-yl]-6-(4-methoxy-benzyloxy)-hexan-3-ol 
• 203925-46-6 1-[(2R,4aR,6R,7R,8R,8aR)-8-Benzyloxy-7-(tert-butyl-dimethyl-silanyloxy)-2-(4-methoxy-phenyl)-hexahydro-pyrano[3,2-d][1,3]dioxin-6-yl]-6-(4-methoxy-benzyloxy)-hexan-3-one 
• 203925-47-7 1-[(2R,4aR,6R,7R,8S,8aR)-8-Benzyloxy-7-hydroxy-2-(4-methoxy-phenyl)-hexahydro-pyrano[3,2-d][1,3]dioxin-6-yl]-6-(4-methoxy-benzyloxy)-hexan-3-one 
• 203925-43-3 3-[(2R,4aR,6R,7R,8R,8aR)-8-Benzyloxy-7-(tert-butyl-dimethyl-silanyloxy)-2-(4-methoxy-phenyl)-hexahydro-pyrano[3,2-d][1,3]dioxin-6-yl]-propan-1-ol 
• 203925-38-6 (2R,3R,4S,5R,6R)-2-Allyl-4-benzyloxy-6-hydroxymethyl-tetrahydro-pyran-3,5-diol 
• 194039-11-7 3-[(2R,4aR,6R,7R,8R,8aR)-8-Benzyloxy-7-(tert-butyl-dimethyl-silanyloxy)-2-(4-methoxy-phenyl)-hexahydro-pyrano[3,2-d][1,3]dioxin-6-yl]-propionaldehyde 
• 203925-41-1 [(2R,4aR,6R,7R,8R,8aR)-6-Allyl-8-benzyloxy-2-(4-methoxy-phenyl)-hexahydro-pyrano[3,2-d][1,3]dioxin-7-yloxy]-tert-butyl-dimethyl-silane 
• 194039-09-3 (2R,4aR,6R,7R,8S,8aR)-6-Allyl-8-benzyloxy-2-(4-methoxy-phenyl)-hexahydro-pyrano[3,2-d][1,3]dioxin-7-ol 

Relevant academic research and scientific papers

SACCHARIDE CONJUGATES

This invention relates to compounds comprising a saccharide conjugated to an imaging agent or a reporter group, compositions comprising them and methods of using them. Specifically BLM-disaccharide and BLM-monosaccharide conjugates containing different linker groups and an imaging agent or a reporter group are provided for the targeting and imaging of tumors.

SUGAR-LINKER-DRUG CONJUGATES

The present disclosure relates to sugar-linker-drug conjugates, of the formula [A-B-]n-L-D, wherein A is a saccharide; B is a spacer, n is an integer selected from 1 to 3; L is a linker group and D is a drug having a chemically reactive functional group selected from the group consisting of a primary or secondary amine, hydroxyl, sulfhydryl, carboxyl, aldehyde and ketone. Pharmaceutical compositions comprising the conjugates and methods of using thern are also provided.

Efficient synthesis of okadaic acid. 1. Convergent assembly of the C15- C38 domain

A convergent synthesis of the C15-C38 domain of the marine natural product okadaic acid is reported. This involved the preparation of intermediates representing the C16-C27 and C28-C38 portions of okadaic acid, their direct coupling, and elaboration to th